Clinical Trial Update: A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial is evaluating the safety and effects of EI-1071 on neuroinflammation in Alzheimer's disease patients; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• EI-1071

Snippet

Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. | Conditions: Mild, Moderate, or Severe Alzheimer's Disease | Phase 2 | Status: RECRUITING